Seer announces publication of study on Proteograph workflow

Seer announced a publication in Nature Communications from a study led by Weill Cornell Medicine showing Seer‘s Proteograph workflow to potentially unveil novel proteogenomic insights into genetics-based drug and biomarker discovery for precision medicines. Designed to address the challenges with affinity-based proteomic approaches for protein quantitative trait loci studies, the scalable, high-resolution Proteograph workflow enables scientists to link genetic variation with protein abundance with peptide level resolution. In the paper, the researchers used Seer’s first-generation Proteograph Assay workflow upstream of mass spectrometry to quantify over 18,000 peptides from approximately 3,000 proteins in more than 320 blood samples to detect and quantify blood-circulating proteins in the presence of protein-altering variants, PAVs. The study found 184 PAVs in 137 genes, confirmed by their variant peptides in mass spectrometry data, known as MS-PAV. Most MS-PAVs were aligned with known genetic markers, validating the target specificity of the method. Some MS-PAVs overlapped with trans-pQTLs, shedding light on potential causal proteins. Lastly, the study revealed proteins overlooked by traditional methods, like the incretin pro-peptide linked to type 2 diabetes and cardiovascular disease.